124 related articles for article (PubMed ID: 27139144)
1. Cyclodextrin-based telmisartan ophthalmic suspension: Formulation development for water-insoluble drugs.
Muankaew C; Jansook P; Sigurđsson HH; Loftsson T
Int J Pharm; 2016 Jun; 507(1-2):21-31. PubMed ID: 27139144
[TBL] [Abstract][Full Text] [Related]
2. yCD/HPyCD mixtures as solubilizer: solid-state characterization and sample dexamethasone eye drop suspension.
Jansook P; Ritthidej GC; Ueda H; Stefánsson E; Loftsson T
J Pharm Pharm Sci; 2010; 13(3):336-50. PubMed ID: 21092707
[TBL] [Abstract][Full Text] [Related]
3. Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension.
Jansook P; Stefánsson E; Thorsteinsdóttir M; Sigurdsson BB; Kristjánsdóttir SS; Bas JF; Sigurdsson HH; Loftsson T
Eur J Pharm Biopharm; 2010 Oct; 76(2):208-14. PubMed ID: 20637867
[TBL] [Abstract][Full Text] [Related]
4. Cyclodextrin-poloxamer aggregates as nanocarriers in eye drop formulations: dexamethasone and amphotericin B.
Jansook P; Pichayakorn W; Muankaew C; Loftsson T
Drug Dev Ind Pharm; 2016 Sep; 42(9):1446-54. PubMed ID: 26765786
[TBL] [Abstract][Full Text] [Related]
5. Novel oral formulation approach for poorly water-soluble drug using lipocalin-type prostaglandin D synthase.
Mizoguchi M; Nakatsuji M; Inoue H; Yamaguchi K; Sakamoto A; Wada K; Inui T
Eur J Pharm Sci; 2015 Jul; 74():77-85. PubMed ID: 25906910
[TBL] [Abstract][Full Text] [Related]
6. Amorphous ternary cyclodextrin nanocomposites of telmisartan for oral drug delivery: improved solubility and reduced pharmacokinetic variability.
Sangwai M; Vavia P
Int J Pharm; 2013 Sep; 453(2):423-32. PubMed ID: 22935741
[TBL] [Abstract][Full Text] [Related]
7. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops.
Loftsson T; Hreinsdóttir D; Stefánsson E
J Pharm Pharmacol; 2007 May; 59(5):629-35. PubMed ID: 17524227
[TBL] [Abstract][Full Text] [Related]
8. Effect of γ-cyclodextrin on solubilization and complexation of irbesartan: influence of pH and excipients.
Muankaew C; Jansook P; Stefánsson E; Loftsson T
Int J Pharm; 2014 Oct; 474(1-2):80-90. PubMed ID: 25128698
[TBL] [Abstract][Full Text] [Related]
9. Influence of hydrophilic polymers on the complexation of carbamazepine with hydroxypropyl-β-cyclodextrin.
Medarević D; Kachrimanis K; Djurić Z; Ibrić S
Eur J Pharm Sci; 2015 Oct; 78():273-85. PubMed ID: 26255049
[TBL] [Abstract][Full Text] [Related]
10. Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer.
Bíró T; Horvát G; Budai-Szűcs M; Csányi E; Urbán E; Facskó A; Szabó-Révész P; Csóka I; Aigner Z
Drug Des Devel Ther; 2018; 12():2529-2537. PubMed ID: 30147300
[TBL] [Abstract][Full Text] [Related]
11. Development of eye drops containing antihypertensive drugs: formulation of aqueous irbesartan/γCD eye drops.
Jansook P; Muankaew C; Stefánsson E; Loftsson T
Pharm Dev Technol; 2015; 20(5):626-32. PubMed ID: 24754413
[TBL] [Abstract][Full Text] [Related]
12. Solubilization of the poorly water soluble drug, telmisartan, using supercritical anti-solvent (SAS) process.
Park J; Cho W; Cha KH; Ahn J; Han K; Hwang SJ
Int J Pharm; 2013 Jan; 441(1-2):50-5. PubMed ID: 23262425
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of γ-cyclodextrin effect on permeation of lipophilic drugs: application of cellophane/fused octanol membrane.
Muankaew C; Jansook P; Loftsson T
Pharm Dev Technol; 2017 Jun; 22(4):562-570. PubMed ID: 27146583
[TBL] [Abstract][Full Text] [Related]
14. Nanocrystallization by evaporative antisolvent technique for solubility and bioavailability enhancement of telmisartan.
Bajaj A; Rao MR; Pardeshi A; Sali D
AAPS PharmSciTech; 2012 Dec; 13(4):1331-40. PubMed ID: 23054986
[TBL] [Abstract][Full Text] [Related]
15. Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole.
Taupitz T; Dressman JB; Buchanan CM; Klein S
Eur J Pharm Biopharm; 2013 Apr; 83(3):378-87. PubMed ID: 23201048
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Evaluation of the Binding of Lipocalin-Type Prostaglandin D Synthase to Poorly Water-Soluble Drugs.
Teraoka Y; Kume S; Lin Y; Atsuji S; Inui T
Mol Pharm; 2017 Oct; 14(10):3558-3567. PubMed ID: 28829147
[TBL] [Abstract][Full Text] [Related]
17. Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea.
Okamoto N; Ito Y; Nagai N; Murao T; Takiguchi Y; Kurimoto T; Mimura O
J Oleo Sci; 2010; 59(8):423-30. PubMed ID: 20625234
[TBL] [Abstract][Full Text] [Related]
18. Screening of mucoadhesive microparticles containing hydroxypropyl-beta-cyclodextrin for the nasal delivery of risperidone.
Jug M; Bećirević-Laćan M
Comb Chem High Throughput Screen; 2007 Jun; 10(5):358-67. PubMed ID: 17896931
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of zaleplon complexation with cyclodextrins and hydrophilic polymers in solution and in solid state.
Jablan J; Szalontai G; Jug M
J Pharm Biomed Anal; 2012 Dec; 71():35-44. PubMed ID: 22898722
[TBL] [Abstract][Full Text] [Related]
20. Nimodipine Ophthalmic Formulations for Management of Glaucoma.
Maria DN; Abd-Elgawad AH; Soliman OA; El-Dahan MS; Jablonski MM
Pharm Res; 2017 Apr; 34(4):809-824. PubMed ID: 28155073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
